Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 13/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | GAPDH | P04406 | 1/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4982895 | 0.86 | MAOB (0.58) | NPC1KDM4ERAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4985668 | 0.84 | MAOB (0.45) | NPC1KDM4ERAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4985424 | 0.76 | APP (0.59) | NPC1KDM4ERAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4992894 | 0.74 | MAOB (0.55) | KDM4EMAOBADORA3TP53MAOA | |
| SCHEMBL4987026 | 0.74 | MAOB (0.55) | NPC1KDM4ERAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL19003439 | 0.73 | ALDH1A1 (0.69) | NPC1KDM4ERAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2356521 | 0.72 | ALDH1A1 (0.35) | ALDH1A1TP53CA1CA2 | |
| SCHEMBL8797496 | 0.69 | HDAC3 (0.40) | NPC1KDM4ERAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL9100211 | 0.68 | CYP19A1 (0.71) | NPC1KDM4ERAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL11827935 | 0.66 | STS (0.51) | NPC1KDM4ERAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8192717-B2 | Flavone derivative, chalcone derivative, styrylchromone derivative, or a coumarin derivative with high binding specificity to an amyloid beta protein, high permeability to a blood-brain barrier, and ability to rapidly disappear from sites other than cerebral senile plaque; also drug screening | NAGASAKI UNIVERSITY (JP) | 2012-06-05 | — | — | US | disclosed |
| US-20080131367-A1 | Composition For Diagnosing Amyloid-Related Diseases | Mori, Hiroshi (JP) | 2008-06-05 | — | — | US | disclosed |
| EP-1815872-A1 | COMPOSITION FOR AMYLOID-ASSOCIATED DISEASE DIAGNOSIS | Nagasaki University (JP) | 2007-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080131367-A1 | Composition For Diagnosing Amyloid-Related Diseases | APP, APBA1, FABP7 | NPC1 146/4885KDM4E 3076/4885RAB9A 2882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.